ATE469963T1 - Identifizierung der virulenz-assoziierten regionen rd1 und rd5, die die entwicklung von verbesserten impfstoffen mit m. bovis bcg und m. microti ermöglicht - Google Patents

Identifizierung der virulenz-assoziierten regionen rd1 und rd5, die die entwicklung von verbesserten impfstoffen mit m. bovis bcg und m. microti ermöglicht

Info

Publication number
ATE469963T1
ATE469963T1 AT02290864T AT02290864T ATE469963T1 AT E469963 T1 ATE469963 T1 AT E469963T1 AT 02290864 T AT02290864 T AT 02290864T AT 02290864 T AT02290864 T AT 02290864T AT E469963 T1 ATE469963 T1 AT E469963T1
Authority
AT
Austria
Prior art keywords
microti
bovis bcg
strains
virulence
identification
Prior art date
Application number
AT02290864T
Other languages
English (en)
Inventor
Stewart Cole
Alexander S Pym
Roland Brosch
Priscille Brodin
Laleh Majlessi
Claude Leclerc
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE469963T1 publication Critical patent/ATE469963T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
AT02290864T 2002-04-05 2002-04-05 Identifizierung der virulenz-assoziierten regionen rd1 und rd5, die die entwicklung von verbesserten impfstoffen mit m. bovis bcg und m. microti ermöglicht ATE469963T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02290864A EP1350839B1 (de) 2002-04-05 2002-04-05 Identifizierung der Virulenz-assoziierten Regionen RD1 und RD5, die die Entwicklung von verbesserten Impfstoffen mit M. bovis BCG und M. microti ermöglicht

Publications (1)

Publication Number Publication Date
ATE469963T1 true ATE469963T1 (de) 2010-06-15

Family

ID=27838170

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07122295T ATE535600T1 (de) 2002-04-05 2002-04-05 Identifizierung der virulenz-assoziierten region rd1, die die entwicklung von verbesserten impstoffen mit m. microti ermöglicht
AT02290864T ATE469963T1 (de) 2002-04-05 2002-04-05 Identifizierung der virulenz-assoziierten regionen rd1 und rd5, die die entwicklung von verbesserten impfstoffen mit m. bovis bcg und m. microti ermöglicht

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07122295T ATE535600T1 (de) 2002-04-05 2002-04-05 Identifizierung der virulenz-assoziierten region rd1, die die entwicklung von verbesserten impstoffen mit m. microti ermöglicht

Country Status (11)

Country Link
US (2) US7883712B2 (de)
EP (4) EP1914299B9 (de)
AT (2) ATE535600T1 (de)
AU (1) AU2003223039A1 (de)
CA (1) CA2481318C (de)
CY (1) CY1110764T1 (de)
DE (1) DE60236573D1 (de)
DK (1) DK1350839T3 (de)
ES (1) ES2346043T3 (de)
PT (1) PT1350839E (de)
WO (1) WO2003085098A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040091A1 (it) 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare.
GB0406271D0 (en) * 2004-03-19 2004-04-21 Isis Innovation Diagnostic test
WO2006117538A2 (en) * 2005-04-29 2006-11-09 Fusion Antibodies Limited Assays for diagnosis of tuberculosis and uses thereof
US8398991B2 (en) * 2005-06-22 2013-03-19 Institut Pasteur Modified ESAT-6 molecules and improved vaccine strains of Mycobacterium bovis BCG
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
WO2008140598A2 (en) * 2006-12-04 2008-11-20 Bacilligen, Inc. Novel immunotherapeutic mycobacteria, pharmaceutic formulations and uses thereof
TR201903223T4 (tr) 2009-04-24 2019-03-21 Statens Seruminstitut Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı.
WO2010132112A2 (en) 2009-05-14 2010-11-18 Wisconsin Alumni Research Foundation Immunogenic compositions against tuberculosis
TR201101874A2 (tr) * 2011-02-25 2011-08-22 Leyla A�An Nac�Ye Yüzeyel mesane tümorü tedavisinde kullanılabilecek mycobacterıum(mikobakteri) brumae hücre duvarı ekstreleri.
GR20120100415A (el) * 2012-08-08 2014-03-17 Νικολαος Χρηστου Πουλακης Μεθοδος αμεσης ανιχνευσης του μυκοβακτηριδιου της φυματιωσης
EP2912056B1 (de) * 2012-10-23 2020-02-12 Statens Serum Institut M.- tuberkulose-impfstoffe
EP3152227B1 (de) * 2014-06-03 2018-09-26 Institut Pasteur Rekombinantes mycobakterium bovis bcg exprimierende antigene des mycobacterium-marinum-esx-1-sekretionssystem
CN104628834B (zh) * 2015-01-23 2016-03-23 中国疾病预防控制中心传染病预防控制所 一种结核感染t细胞免疫检测抗原及其应用
CN104678097B (zh) * 2015-03-10 2017-04-05 中国人民解放军军事医学科学院基础医学研究所 一种用于肺结核诊断的结核分枝杆菌组合抗原
CN109406777B (zh) * 2017-08-18 2022-02-18 中国科学院生物物理研究所 用于特异性检测结核分枝杆菌感染的蛋白Rv2824c
CN109406776B (zh) * 2017-08-18 2022-02-11 中国科学院生物物理研究所 用于特异性检测结核分枝杆菌感染的蛋白Rv2818c
EP3643398B1 (de) 2018-10-25 2021-07-07 Heraeus Medical GmbH Vorrichtung und verfahren zum bereitstellen von knochenzement
DE102018131268B4 (de) 2018-12-07 2021-11-25 Heraeus Medical Gmbh Vorrichtung zum Mischen eines Knochenzements mit Hohlraum zum Monomertransfer
DE102018131266B4 (de) 2018-12-07 2021-12-23 Heraeus Medical Gmbh Vorrichtung zum Mischen eines Knochenzements mit Hohlraum zum Monomertransfer und Verfahren zur Herstellung eines Knochenzementteigs
CN110763843B (zh) * 2019-11-06 2020-09-15 华中农业大学 一种牛支原体双抗夹心elisa检测试剂盒及其应用
CN116173213A (zh) * 2023-01-16 2023-05-30 武汉大学 Rv1977在制备抗结核分枝杆菌感染药物中的应用
CN120966730A (zh) * 2025-10-21 2025-11-18 华南理工大学 一种基因改造牛分枝杆菌减毒菌株及其构建方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096879A (en) 1978-12-18 2000-08-01 Institut Pasteur Nucleotide sequence comprising the genome of hepatitis B virus, nucleotide sequence coding the surface antigen of the hepatitis B virus, vectors containing the nucleotide sequences, process for the preparation thereof, and antigen obtained thereby
DE3176404D1 (en) 1980-04-22 1987-10-08 Pasteur Institut Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine
DE3587512T2 (de) 1984-10-18 1993-12-02 Centre Nat Rech Scient Hüllenantigene vom menschlichen Immunodefizienz-Virus und deren Verwendungen.
FR2682122B1 (fr) 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
FR2735478B1 (fr) 1995-06-13 1997-08-22 Pasteur Institut Molecules polypeptidiques de stade pre-erythrocytaire du paludisme
FR2744724B1 (fr) 1996-02-14 2002-08-02 Pasteur Institut Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
AU8123898A (en) * 1997-07-16 1999-02-10 Institut Pasteur A polynucleotide functionally coding for the lhp protein from mycobacterium tuberculosis, its biologically active derivative fragments, as well as metho ds usingthe same
EP1058731A2 (de) * 1998-03-06 2000-12-13 Statens Seruminstitut Herstellung von mykobacterien-polypeptidens bei milchsaüre-bacterien
US6294328B1 (en) * 1998-06-24 2001-09-25 The Institute For Genomic Research DNA sequences for strain analysis in Mycobacterium tuberculosis
CA2372583C (en) * 1999-05-04 2012-07-10 University Of Medicine And Dentistry Of New Jersey Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines
DE60219589T2 (de) 2002-02-25 2008-02-14 Institut Pasteur Spezifisch vom Genom von Mycobacterium tuberculosis deletierte Sequenzen und deren Verwendung in der Diagnostik und als Vakzine

Also Published As

Publication number Publication date
EP1914299B9 (de) 2012-05-02
DK1350839T3 (da) 2010-07-12
EP1350839B1 (de) 2010-06-02
AU2003223039A8 (en) 2003-10-20
CY1110764T1 (el) 2015-06-10
EP2302033A3 (de) 2012-03-07
AU2003223039A1 (en) 2003-10-20
US7883712B2 (en) 2011-02-08
EP1914299A3 (de) 2008-05-21
US8747866B2 (en) 2014-06-10
CA2481318A1 (en) 2003-10-16
US20050220811A1 (en) 2005-10-06
EP2302033A2 (de) 2011-03-30
ES2346043T3 (es) 2010-10-08
ATE535600T1 (de) 2011-12-15
CA2481318C (en) 2014-06-10
EP1492867A2 (de) 2005-01-05
PT1350839E (pt) 2010-08-12
EP1914299A2 (de) 2008-04-23
EP1914299B1 (de) 2011-11-30
EP1350839A1 (de) 2003-10-08
HK1059803A1 (en) 2004-07-16
WO2003085098A3 (en) 2004-01-29
WO2003085098A2 (en) 2003-10-16
DE60236573D1 (de) 2010-07-15
US20120189662A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
ATE469963T1 (de) Identifizierung der virulenz-assoziierten regionen rd1 und rd5, die die entwicklung von verbesserten impfstoffen mit m. bovis bcg und m. microti ermöglicht
EP4523756A3 (de) Immunotherapeutischer impfstoff und antikörperkombinationstherapie
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
WO2008112344A3 (en) Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
TNSN07387A1 (en) C.perfringens alpha toxoid vaccine
JP2012041355A5 (de)
WO2019033043A3 (en) Anti-cd8 antibodies and uses thereof
NZ759686A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2007003402A (es) Composicion inmunogena para su uso en vacunacion contra estafilococos.
TW200722101A (en) Novel composition
NO20015073D0 (no) Vaksiner
EP2385059A3 (de) Verfahren und Zusammensetzungen zum Auslösen von multivalenten Immunreaktionen gegen auf Krebszellen und Tumor-Stroma exprimierte dominante und subdominante Epitope
WO2017044803A8 (en) Expression vector delivery system and use thereof for inducing an immune response
WO2023049636A3 (en) Cancer therapy compositions and uses thereof
Lu et al. Novel recombinant BCG coexpressing Ag85B, ESAT‐6 and Rv2608 elicits significantly enhanced cellular immune and antibody responses in C57BL/6 mice
WO2006071983A3 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2005061534A3 (en) Improved tuberculosis vaccines
WO2003090687A3 (en) Using heat shock proteins to increase immune response
TN2012000592A1 (en) Vaccine compositions based on sticholysin encapsulated in liposomes
WO2010080188A3 (en) Epitope targeted anthrax vaccine
Gu et al. The Mycobacterium bovis BCG prime-Rv0577 DNA boost vaccination induces a durable Th1 immune response in mice
Moradi et al. A new DNA vaccine expressing HspX-PPE44-EsxV fusion antigens of Mycobacterium tuberculosis induced strong immune responses
WO2007075308A3 (en) Vaccine candidates against johne's disease
WO2020227605A3 (en) Dna encoded il-36 gamma as an adjuvant
DE60325586D1 (de) Mycobakterielle Proteinantigene für Krebstherapie und Impfung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1350839

Country of ref document: EP